Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 1 day agoScore70
Body
postMONARCH:
Abemaciclib After CDK4/6 Inhibitor Progression — PFS Benefit Without a Statistically Significant OS Improvement
@OncoAlert #BreastCancer #bcsm #ESMO26
54 views · 6 likes · 1 repost · 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: Aya Mohamed | MSc, MD 🎗 · x.com